

Performance Against Initiation Benchmark

REC Number	IRAS Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Reasons for delay correspond to:
14/LO/1885	151063	EDIBLE v1.0	22/12/2015		Neither
15/SS/0186	190856	Protocol 083: MK5172A + Sofosbuvir +/-RBV in Cirrhotic GT3 Subjects (MK-5172-083)	19/01/2016	28/01/2016	Benchmark Met
15/WS/0121	173661	Propel 004 - MSB0010718C in NSCLC - EMR100070004:Phase III study of avelumab vs docetaxel in NSCLC -	20/01/2016	03/03/2016	Benchmark Met
14/NE/0103	141927	A randomised double blind dose non-inferiority trial of aspirin in Lynch syndrome	14/01/2016	13/04/2016	Neither
15/SC/0603	114842	CCRN 2393 MAESTRO-OL	26/01/2016	01/03/2016	Benchmark Met
14/SC/1329	157664	STRIVE	27/01/2016		Neither
15/SW/0008	163427	The Bluebelle study (Phase B)	22/01/2016	01/03/2016	Benchmark Met
14/SC/1290	141516	TREATT: Trial to EvaluAte Tranexamic acid therapy in Thrombocytopenia	27/01/2016	19/02/2016	Benchmark Met
14/WA/1118	159836	Postoperative adjuvant treatment for HPVpositive tumours (PATHOS)	01/02/2016	09/02/2016	Benchmark Met
15/NW/0416	167060	MUK8	02/02/2016	13/09/2016	Neither
15/WM/0415	194417	PRIMAL	26/01/2016	23/02/2016	Benchmark Met
15/SC/0409	183061	OPHT 4170 (AMD) - SEQUOIA	03/02/2016	05/04/2016	Benchmark Met
15/EE/0405	189187	DIAB 4501	03/02/2016	01/05/2016	Sponsor
15/YH/0407	183603	Single Dose of MK0517 for Prevention of CINV in Paediatric Subjects	05/02/2016		Sponsor
15/EM/0300	180135	WO29636 - MPDL3280A in muscle invasive bladder cancer	26/01/2016		Neither
15/SC/0456	174561	CANC - 4254 - Anti-Pd-L1 Antibody (MPDL3280A) in Pediatric and Young Adult	09/02/2016	24/03/2016	Benchmark Met
14/EM/1284	159662	Neo-AEGIS	07/01/2016	02/03/2016	Benchmark Met
14/YH/0128	150031	SaFaRI (SNS versus the FENIX MSA for adult FI)	15/02/2016	22/02/2016	Benchmark Met
15/LO/2098	182147	INTEREST: FP-1201-lyo for the treatment of ARDS	22/01/2016	04/04/2016	Sponsor
15/SW/0326	189007	ATLAS: JNJ56021927 (ARN509)	18/02/2016	15/03/2016	Benchmark Met
15/WM/0363	184648	COBALT: Study of Obeticholic Acid in Primary Biliary Cirrhosis (747-302)	26/01/2016	13/04/2016	NHS Provider
15/NE/0167	171524	MLN9708 in Multiple Myeloma Not Treated with Stem Cell transplantation - MILLENIUM	08/03/2016	04/10/2016	Neither
15/SW/0179	167604	Injectable Valve Implantation Trial (Invite)	16/02/2016	11/07/2016	Neither
14/LO/1206	154429	PLATFORM	22/02/2016	27/04/2016	Benchmark Met
15/EM/0437	184390	COLUMBUS-AMD	22/03/2016	01/06/2016	Sponsor
15/SC/0103	154496	SCALOP-2: Systemic therapy and Chemoradiation in Advanced LOcalised Pancreatic cancer - 2	22/03/2016	27/04/2016	Benchmark Met
16/SW/0032	190476	My Health Tags - To Improve Taking Tablets For Heart Failure	23/03/2016	14/06/2016	Sponsor
15/NI/00243	191267	Study of CTX 4430 in Cystic Fibrosis Patients	31/03/2016	22/09/2016	Neither
15/LO/1464	174042	DARS	29/03/2016	23/09/2016	Neither
15/NE/0274	181026	EORTC 1320	24/03/2016	05/07/2016	Neither
14/EE/1293	164389	C-STICH	25/02/2016	16/06/2016	Both
14/LO/1644	137028	WT1TCR -002 Phase I/II study of genemodified WT1 TCR therapy in MDS & AML patient	28/04/2016	27/07/2016	Sponsor
15/LO/0141	169126	OPHT 3845	24/03/2016		Sponsor
15/LO/0413	171579	Safety and Efficacy of Brimonidine-DDS in patients with GA-AMD	12/05/2016	01/07/2016	Benchmark Met
15/LO/0710	177905	EMBARK:MDV3100-13 Phase3, Enzalutamide, nonmetastatic Prostate Cancer	17/05/2016		Neither
15/YH/0478	186697	REGENERATE: A Phase 3, DoubleBlind, Randomized, LongTerm, PlaceboControlled, Multicenter Study	26/05/2016		Neither
15/ES/0001	193859	GED-0301-CD-002 PhIII study for subjects with Active Crohn?s Disease (REVOLVE)	27/04/2016	09/09/2016	Sponsor
14/LO/2061	162162	Positioning in Macular Hole Surgery	07/06/2016	02/12/2016	Both

Performance Against Initiation Benchmark

15/EE/0464	183877	CRIT 4440					03/06/2016		14/09/2016	Sponsor
14/ES/1064	143994	LOGS - A randomised phase II/II study to assess the efficacy of Trametinib (GSK 1120212) in patients with					15/06/2016			Neither
15/WA/0316	182694	MyeChild 01					15/06/2016		19/10/2016	Neither
14/NW/1110	149572	rEECur					29/03/2016			Neither
14/SC/1416	156215	Immunoglobulin in the Treatment of Encephalitis (The IgNiTE study)					23/03/2016			Neither
15/LO/0769	155035	Left Atrial Appendage Occlusion Study III (LAAOS III)					27/07/2016		27/11/2016	Sponsor
16/SW/0069	181429	Dynamic hormone diagnostics (ULTRADIAN)					29/02/2016		03/10/2016	Sponsor
16/EE/0105	191013	ZOL-A trial					26/09/2016			Neither
REC Number	IRAS Number	Name of Trial	HRA Approval Date	Date Site Invited	Date Site Selected	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
16/LO/0814	199311	CHIL4593 - Sarilumab, administered with subcutaneous (SC) injection, in patients aged 2 to 17, with polyarticular-course juvenile idiopathic arthritis (pcJIA) followed by an extension phase	06/07/2016	07/04/2016	05/05/2016	16/08/2016	17/08/2016	05/09/2016		Neither
16/WM/0276	207822	Safety of Nasal Influenza Immunisation in Children with Asthma: The SNIFFLE 4 study	22/08/2016	08/07/2016	05/10/2016	05/10/2016	11/10/2016	13/10/2016	20/10/2016	Benchmark Met
16/WM/0359	211812	Blinatumomab in Aggressive B-Cell Non Hodgkin Lymphoma	12/10/2016	24/08/2016	27/10/2016	03/11/2016	03/11/2016	23/11/2016		70 days not yet reached
16/LO/0581	194313	C31004	11/08/2016	01/08/2016	14/09/2016	25/10/2016	16/11/2016			Both
16/EE/0243	207331	EARN 30709	01/08/2016	22/08/2016	10/10/2016	16/11/2016	17/11/2016			Sponsor
16/SC/0161	186322	GO29438 Phase III Study-Atezolizumab with chemotherapy in Stage IV Non-Squamous	12/05/2016	23/09/2016	16/11/2016	01/12/2016	01/12/2016	05/12/2016	22/12/2016	Benchmark Met
16/SC/0542	208245	OMASPECT	09/11/2016	04/11/2016	25/11/2016	29/11/2016	19/12/2016			70 days not yet reached
16/EM/0408	211983	A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma	02/12/2016	18/10/2016	05/12/2016	22/12/2016	23/12/2016	29/12/2016		70 days not yet reached
16/NW/0750	209722	A study to evaluate the acceptability of ZestiVits;	09/11/2016	06/09/2016	01/11/2016	02/11/2016	17/11/2016			70 days not yet reached
16/WA/0159	162019	EMPHIS	05/12/2016		05/12/2016	05/12/2016	06/12/2016			70 days not yet reached
16/LO/0543	198734	GMP Drink for PKU Study	07/07/2016	27/10/2016	16/11/2016	06/12/2016	07/12/2016			70 days not yet reached